Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Kaufman B, et al. Among authors: balmana j. J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3. J Clin Oncol. 2015. PMID: 25366685 Free PMC article. Clinical Trial.
BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families.
Campos B, Diez O, Domènech M, Baena M, Pericay C, Balmaña J, del Rio E, Sanz J, Alonso C, Baiget M. Campos B, et al. Among authors: balmana j. Ann Oncol. 2001 Dec;12(12):1699-703. doi: 10.1023/a:1013517313008. Ann Oncol. 2001. PMID: 11843247 Free article.
BRCA in breast cancer: ESMO clinical recommendations.
Balmaña J, Díez O, Castiglione M; ESMO Guidelines Working Group. Balmaña J, et al. Ann Oncol. 2009 May;20 Suppl 4:19-20. doi: 10.1093/annonc/mdp116. Ann Oncol. 2009. PMID: 19454451 Free article. Review. No abstract available.
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM. Pierce LJ, et al. Among authors: balmana j. Breast Cancer Res Treat. 2010 Jun;121(2):389-98. doi: 10.1007/s10549-010-0894-z. Epub 2010 Apr 22. Breast Cancer Res Treat. 2010. PMID: 20411323 Free PMC article.
BRCA in breast cancer: ESMO Clinical Practice Guidelines.
Balmaña J, Diez O, Rubio I, Castiglione M; ESMO Guidelines Working Group. Balmaña J, et al. Ann Oncol. 2010 May;21 Suppl 5:v20-2. doi: 10.1093/annonc/mdq161. Ann Oncol. 2010. PMID: 20555082 Free article. No abstract available.
Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J. Graña B, et al. Among authors: balmana j. Breast Cancer Res Treat. 2011 Jul;128(2):573-9. doi: 10.1007/s10549-011-1462-x. Epub 2011 Mar 29. Breast Cancer Res Treat. 2011. PMID: 21445571
Evidence for a link between TNFRSF11A and risk of breast cancer.
Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Mariette F, Bernard L, Radice P, Kaufman B, Laitman Y, Milgrom R, Friedman E, Sáez ME, Climent F, Soler MT, Diez O, Balmaña J, Lasa A, Ramón y Cajal T, Miramar MD, de la Hoya M, Pérez-Segura P, Caldés T, Moreno V, Urruticoechea A, Brunet J, Lázaro C, Blanco I, Pujana MA, González-Suárez E. Bonifaci N, et al. Among authors: balmana j. Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4. Breast Cancer Res Treat. 2011. PMID: 21541702
BRCA in breast cancer: ESMO Clinical Practice Guidelines.
Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. Balmaña J, et al. Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4. doi: 10.1093/annonc/mdr373. Ann Oncol. 2011. PMID: 21908500 Free article. No abstract available.
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
Domchek SM, Mitchell G, Lindeman GJ, Tung NM, Balmaña J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedlander M, Kaufman B, Garber JE, Tutt A, Robson ME. Domchek SM, et al. Among authors: balmana j. J Clin Oncol. 2011 Nov 10;29(32):4224-6. doi: 10.1200/JCO.2011.36.8134. Epub 2011 Sep 19. J Clin Oncol. 2011. PMID: 21931031 No abstract available.
232 results